Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

European Notebook: Price Freezes, European Elections To Feature In 2014

Executive Summary

This month’s European Notebook scans the horizon for European legislative and regulatory changes affecting the pharmaceutical industry in the next 12 months, including drug price freezes in Germany and the U.K., the heated debate over clinical trial data transparency, the start of the EU unitary patent, and more.

You may also be interested in...



Thousands Of Jobs May Go At Novartis But Worker Headcount To Stay Flat

Novartis plans to support new product launches and other activities around the world by re-allocating up to 4,000 positions, in order to make productivity gains.

Deals Of The Week: New Remedies Sought From Nature And Old Technologies

Sanofi links with researchers at Germany’s Fraunhofer Gesellschaft in the search for new antibiotics while a European joint venture called Hit Discovery Constance GmbH is set up to conduct high-throughput screening for biotech and academic partners. Also, Moderna Therapeutics bags another major partner, GSK exits its DMD deal with Prosensa, and more.

German Ruling Will Prevent Original Products Being Split For Distribution

A German court ruling should protect high-cost original product drugs from being split by re-packagers and sold in smaller batches for profit.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

PS055883

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel